Exact Sciences’ biggest priority after Cologuard is lung cancer test

Exact Sciences CFO Jeff Elliott says the foundation laid with Cologuard will help bring to market other screening tools, such as a lung cancer test.

Elliott gave a promising update on Cologuard and laid out the Madison-based company’s plans at a recent Wisconsin Technology Council luncheon in Madison.

Exact Sciences’ noninvasive Cologuard test screens for colon cancer, one of the most deadly forms of cancer.

“Cologuard is really the first product in what we see as a series of diagnostics,” Elliott said.